WSTAM
EVLO

Wilbanks Smith & Thomas Asset Management’s Evelo Biosciences, Inc. Common Stock EVLO Stock Holding History

Wilbanks Smith & Thomas Asset Management’s Portfolio EVLO Stock Details EVLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-45
Closed -$11K – 1398
2018
Q3 		$11K Buy
+45
New +$11.8K ﹤0.01% 1029

Other funds holding EVLO

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Wilbanks Smith & Thomas Asset Management's EVLO Position: Q4 2018 in Review

Wilbanks Smith & Thomas Asset Management sold out of Evelo Biosciences, Inc. Common Stock (EVLO) in Q4 2018, closing a stake of 45 shares — an estimated $11K sold.

Wilbanks Smith & Thomas Asset Management first reported a position in EVLO in Q3 2018 and held it in 1 quarter. The position peaked at $11K in Q3 2018. 40 funds tracked by Wall St. Rank hold EVLO as of Q4 2018.

  • Wilbanks Smith & Thomas Asset Management reported no remaining Evelo Biosciences, Inc. Common Stock position as of Q4 2018 after selling out during the quarter.
  • Wilbanks Smith & Thomas Asset Management sold 45 Evelo Biosciences, Inc. Common Stock shares in Q4 2018, an estimated $11K.
  • Wilbanks Smith & Thomas Asset Management first reported a position in Evelo Biosciences, Inc. Common Stock in Q3 2018 and held it in 1 quarter.
  • Wilbanks Smith & Thomas Asset Management's Evelo Biosciences, Inc. Common Stock position peaked at $11K in Q3 2018.
  • 40 funds tracked by Wall St. Rank held Evelo Biosciences, Inc. Common Stock as of Q4 2018.

Based on Wilbanks Smith & Thomas Asset Management's 13F filing for Q4 2018, filed 8 Feb 2019.